NCT04506242View on ClinicalTrials.gov

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

74

Participants

Timeline

Start Date

September 15, 2020

Primary Completion Date

December 30, 2021

Study Completion Date

December 30, 2025

Conditions

NSCLC

Interventions

DRUG

SHR-1210

PD-1

DRUG

Apatinib

VEGFR2

All Listed Sponsors

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER